==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1186 which contains 4 entries.


Entry 1
(1) Primary information
ID1768
ThPP IDTh1186
Therapeutic Peptide/Protein NameHuman rabies virus immune globulin
SequenceNA view full sequnce in fasta
Functional ClassificationIIIa
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeNA
DescriptionNA
Indication/DiseaseIt is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with HDCV Rabies Vaccine in a pre-exposure or postexposure treatment series should receive only vaccine.
PharmacodynamicsNA
Mechanism of ActionIt provides passive protection by neutralizing the rabies virus when given to individuals exposed to rabies virus. When a rabies immune globulin dose of 20 IU/kg was given simultaneously with the first dose of rabies vaccine, levels of passive anti-rabies antibody were detected 24 hours after injection in all individuals. There was minimal or no interference with the immune response to the initial and subsequent doses of rabies vaccine, including booster doses.
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionLive virus vaccines, such as measles vaccine, should not be given for four months following Human rabies virus immune globulin administration because antibodies in the immune globulin preparation may interfere with the immune response to the vaccine.
TargetNA
Information of corresponding available drug in the market
Brand NameHyperab Rabies Immune Globulin Human
CompanyCutter Med & Biol, Division Of Miles Canada Ltd.
Brand Discription
Prescribed for
Chemical Name
Formulation16.50%
Physcial AppearanceLiquid
Route of Administrationintramuscular
Recommended DosageThe recommended dose for HyperRAB S/D is 20 IU/kg (0.133 mL/kg) of body weight given preferably at the time of the first vaccine dose
ContraindicationHypersensitivity
Side EffectsFever, pain, soreness, tenderness, or stiffness at the injection site, Skin rash
Useful Linkhttps://www.drugs.com/
PubMed ID10675760
3-D StructureN.A.


Entry 2
(2) Primary information
ID1769
ThPP IDTh1186
Therapeutic Peptide/Protein NameHuman rabies virus immune globulin
SequenceNA view full sequnce in fasta
Functional ClassificationIIIa
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeNA
DescriptionNA
Indication/DiseaseIt is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with HDCV Rabies Vaccine in a pre-exposure or postexposure treatment series should receive only vaccine.
PharmacodynamicsNA
Mechanism of ActionIt provides passive protection by neutralizing the rabies virus when given to individuals exposed to rabies virus. When a rabies immune globulin dose of 20 IU/kg was given simultaneously with the first dose of rabies vaccine, levels of passive anti-rabies antibody were detected 24 hours after injection in all individuals. There was minimal or no interference with the immune response to the initial and subsequent doses of rabies vaccine, including booster doses.
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionLive virus vaccines, such as measles vaccine, should not be given for four months following Human rabies virus immune globulin administration because antibodies in the immune globulin preparation may interfere with the immune response to the vaccine.
TargetNA
Information of corresponding available drug in the market
Brand NameHyperrab S/d
CompanyGrifols Therapeutics Inc
Brand DiscriptionRabies immune globulin is used together with rabies vaccine to prevent infection caused by the rabies virus. Rabies immune globulin works by giving your body the antibodies it needs to protect it against the rabies virus.
Prescribed forRabies immune globulin is used together with rabies vaccine to prevent infection caused by the rabies virus.
Chemical NameNA
Formulation150 unit
Physcial AppearanceSolution
Route of Administrationintramuscular
Recommended DosageThe recommended dose for HyperRAB S/D is 20 IU/kg (0.133 mL/kg) of body weight given preferably at the time of the first vaccine dose
ContraindicationHypersensitivity
Side EffectsFever, pain, soreness, tenderness, or stiffness at the injection site, Skin rash
Useful Linkhttps://www.drugs.com/cons/hyperrab-s-d.html
PubMed ID10675760
3-D StructureN.A.


Entry 3
(3) Primary information
ID1770
ThPP IDTh1186
Therapeutic Peptide/Protein NameHuman rabies virus immune globulin
SequenceNA view full sequnce in fasta
Functional ClassificationIIIa
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeNA
DescriptionNA
Indication/DiseaseIt is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with HDCV Rabies Vaccine in a pre-exposure or postexposure treatment series should receive only vaccine.
PharmacodynamicsNA
Mechanism of ActionIt provides passive protection by neutralizing the rabies virus when given to individuals exposed to rabies virus. When a rabies immune globulin dose of 20 IU/kg was given simultaneously with the first dose of rabies vaccine, levels of passive anti-rabies antibody were detected 24 hours after injection in all individuals. There was minimal or no interference with the immune response to the initial and subsequent doses of rabies vaccine, including booster doses.
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionLive virus vaccines, such as measles vaccine, should not be given for four months following Human rabies virus immune globulin administration because antibodies in the immune globulin preparation may interfere with the immune response to the vaccine.
TargetNA
Information of corresponding available drug in the market
Brand NameImogam Rabies Inj 150unit/ml
CompanyPasteur mÉrieux Serums Et Vaccins, s.a.
Brand DiscriptionImogam Rabies Pasteurised is a medicine containing the active ingredient(s) rabies virus immunoglobulin.
Prescribed forRabies immune globulin is used together with rabies vaccine to prevent infection caused by the rabies virus.
Chemical Name
Formulation151 unit
Physcial AppearanceClear, pale yellow to light brown liquid
Route of Administrationintramuscular
Recommended DosageThe recommended dose of IMOGAM® Rabies is 20 IU/kg (0.133 mL/kg) of body weight at the time of administration of the first dose of rabies vaccine.
ContraindicationIMOGAM® Rabies should not be administered as repeat doses once rabies vaccination has been in itiated. Repeating the dose may interfere with maximum active immunity expected to develop from the rabies vaccine.
Side EffectsHypotension, Tachycardia, Nausea, Vomiting, Local reaction, Fever, chills, Allergic type reaction, Anaphylactic shock, General prurit, Rash
Useful Linkhttp://rxisk.org/drug/2227/Rabies-Immune-Globulin-(Human)/92364/Imogam-Rabies-Pasteurized/
PubMed ID10675760
3-D StructureN.A.


Entry 4
(4) Primary information
ID1771
ThPP IDTh1186
Therapeutic Peptide/Protein NameHuman rabies virus immune globulin
SequenceNA view full sequnce in fasta
Functional ClassificationIIIa
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeNA
DescriptionNA
Indication/DiseaseIt is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with HDCV Rabies Vaccine in a pre-exposure or postexposure treatment series should receive only vaccine.
PharmacodynamicsNA
Mechanism of ActionIt provides passive protection by neutralizing the rabies virus when given to individuals exposed to rabies virus. When a rabies immune globulin dose of 20 IU/kg was given simultaneously with the first dose of rabies vaccine, levels of passive anti-rabies antibody were detected 24 hours after injection in all individuals. There was minimal or no interference with the immune response to the initial and subsequent doses of rabies vaccine, including booster doses.
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionLive virus vaccines, such as measles vaccine, should not be given for four months following Human rabies virus immune globulin administration because antibodies in the immune globulin preparation may interfere with the immune response to the vaccine.
TargetNA
Information of corresponding available drug in the market
Brand NameImogam Rabies Pasteurized
CompanySanofi Pasteur Limited
Brand DiscriptionIMOGAM® Rabies Pasteurized [Rabies Immune Globulin (RIG), Pasteurized (Human)] is a sterile solution of antirabies immune globulins (10-16% protein) for intramuscular administration.
Prescribed forIt is indicated for post-exposure prophylaxis in persons suspected of exposure to rabies, who have not previously received a complete immunization regimen with a cell culture produced rabies vaccine.
Chemical Name
FormulationHuman proteins (100-160 mg) containing IgG-class human rabies immune globulins with a minimum titre of 150 IU/mL. Supplied in 2 mL vial s (300 IU) and 10 mL vials (1,500 IU).
Physcial AppearanceSolution
Route of Administrationintramuscular
Recommended DosageThe recommended dose of IMOGAM® Rabies Pasteurized is 20 IU/kg (0.133 mL/kg) of body weight at the time of administration of the first dose of rabies vaccine.
ContraindicationIMOGAM® Rabies Pasteurized should not be administered as repeat doses once rabies vaccination has been in itiated. Repeating the dose may interfere with maximum active immunity expected to develop from the rabies vaccine.
Side EffectsHypotension, Tachycardia, Nausea, Vomiting, Local reaction, Fever, chills, Allergic type reaction, Anaphylactic shock, General prurit, Rash
Useful Linkhttps://www.vaccineshoppecanada.com/document.cfm?file=imogam_rabies_e.pdf
PubMed ID10675760
3-D StructureN.A.